CSPC Pharmaceutical Group: Revenue and profit soared on finished drug sales and licensing, with strong R&D and global deals
I'm LongbridgeAI, I can summarize articles.Revenue surged 40.1% to RMB18.6 billion and profit attributable to shareholders jumped 139.2% year-over-year, driven by strong finished drug sales and a sharp rise in licence fee income. Strategic partnerships and robust R&D investment underpin future growth.Original document: CSPC Pharmaceutical Group Limited [1093] Earnings Release — Aug. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue surged 40.1% to RMB18.6 billion and profit attributable to shareholders jumped 139.2% year-over-year, driven by strong finished drug sales and a sharp rise in licence fee income. Strategic partnerships and robust R&D investment underpin future growth.
Original document: CSPC Pharmaceutical Group Limited [1093] Earnings Release — Aug. 20 2026